Copyright Reports & Markets. All rights reserved.

Global Non-Invasive Cancer Diagnostics Market Professional Survey Report 2019

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Non-Invasive Cancer Diagnostics Industry
  • 1.7 COVID-19 Impact: Non-Invasive Cancer Diagnostics Market Trends

    • 2 Global Non-Invasive Cancer Diagnostics Quarterly Market Size Analysis

    • 2.1 Non-Invasive Cancer Diagnostics Business Impact Assessment - COVID-19
      • 2.1.1 Global Non-Invasive Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Non-Invasive Cancer Diagnostics Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Non-Invasive Cancer Diagnostics Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Non-Invasive Cancer Diagnostics Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Non-Invasive Cancer Diagnostics Market
    • 3.4 Key Players Non-Invasive Cancer Diagnostics Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Non-Invasive Cancer Diagnostics Segments, By Type

    • 4.1 Introduction
      • 1.4.1 CTCs
      • 1.4.2 CTNAS
      • 1.4.3 Exosomes
    • 4.2 By Type, Global Non-Invasive Cancer Diagnostics Market Size, 2019-2021

    5 Impact of Covid-19 on Non-Invasive Cancer Diagnostics Segments, By Application

    • 5.1 Overview
      • 5.5.1 Blood
      • 5.5.2 Urine
      • 5.5.3 Saliva
    • 5.2 By Application, Global Non-Invasive Cancer Diagnostics Market Size, 2019-2021
      • 5.2.1 By Application, Global Non-Invasive Cancer Diagnostics Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Gen-Probe Inc
      • 7.1.1 Gen-Probe Inc Business Overview
      • 7.1.2 Gen-Probe Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.1.3 Gen-Probe Inc Non-Invasive Cancer Diagnostics Product Introduction
      • 7.1.4 Gen-Probe Inc Response to COVID-19 and Related Developments
    • 7.2 Digene Corporation
      • 7.2.1 Digene Corporation Business Overview
      • 7.2.2 Digene Corporation Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.2.3 Digene Corporation Non-Invasive Cancer Diagnostics Product Introduction
      • 7.2.4 Digene Corporation Response to COVID-19 and Related Developments
    • 7.3 Quest Diagnostics Inc
      • 7.3.1 Quest Diagnostics Inc Business Overview
      • 7.3.2 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.3.3 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Product Introduction
      • 7.3.4 Quest Diagnostics Inc Response to COVID-19 and Related Developments
    • 7.4 Cancer, Genetics Inc
      • 7.4.1 Cancer, Genetics Inc Business Overview
      • 7.4.2 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.4.3 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Product Introduction
      • 7.4.4 Cancer, Genetics Inc Response to COVID-19 and Related Developments
    • 7.5 BIOVIEW Inc
      • 7.5.1 BIOVIEW Inc Business Overview
      • 7.5.2 BIOVIEW Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.5.3 BIOVIEW Inc Non-Invasive Cancer Diagnostics Product Introduction
      • 7.5.4 BIOVIEW Inc Response to COVID-19 and Related Developments
    • 7.6 AVIVA Biosciences Corporation
      • 7.6.1 AVIVA Biosciences Corporation Business Overview
      • 7.6.2 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.6.3 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Product Introduction
      • 7.6.4 AVIVA Biosciences Corporation Response to COVID-19 and Related Developments
    • 7.7 Laboratory Corporation of America Holdings (LabCorp)
      • 7.7.1 Laboratory Corporation of America Holdings (LabCorp) Business Overview
      • 7.7.2 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.7.3 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Product Introduction
      • 7.7.4 Laboratory Corporation of America Holdings (LabCorp) Response to COVID-19 and Related Developments
    • 7.8 A&G Pharmaceutical
      • 7.8.1 A&G Pharmaceutical Business Overview
      • 7.8.2 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.8.3 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Product Introduction
      • 7.8.4 A&G Pharmaceutical Response to COVID-19 and Related Developments
    • 7.9 Affymetrix Inc
      • 7.9.1 Affymetrix Inc Business Overview
      • 7.9.2 Affymetrix Inc Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.9.3 Affymetrix Inc Non-Invasive Cancer Diagnostics Product Introduction
      • 7.9.4 Affymetrix Inc Response to COVID-19 and Related Developments
    • 7.10 Precision Therapeutics
      • 7.10.1 Precision Therapeutics Business Overview
      • 7.10.2 Precision Therapeutics Non-Invasive Cancer Diagnostics Quarterly Revenue, 2020
      • 7.10.3 Precision Therapeutics Non-Invasive Cancer Diagnostics Product Introduction
      • 7.10.4 Precision Therapeutics Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Non-Invasive Cancer Diagnostics, including the following market information:
      Global Non-Invasive Cancer Diagnostics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Non-Invasive Cancer Diagnostics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Non-Invasive Cancer Diagnostics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Non-Invasive Cancer Diagnostics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Cancer, Genetics Inc, BIOVIEW Inc, AVIVA Biosciences Corporation, Laboratory Corporation of America Holdings (LabCorp), A&G Pharmaceutical, Affymetrix Inc, Precision Therapeutics, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      CTCs
      CTNAS
      Exosomes

      Based on the Application:
      Blood
      Urine
      Saliva

      Buy now